Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase NA 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Neoplasms 1Multiple Endocrine Neoplasia Type 2a 1

Interventions

pembrolizumab 66Carboplatin 65Paclitaxel 54Magnetic Resonance Spectroscopy 45Cisplatin 45Specimen Handling 43Gemcitabine 36Docetaxel 31Bevacizumab 31Leucovorin 29Doxorubicin 29Dexamethasone 28Fluorouracil 27Pemetrexed 26Cyclophosphamide 26Oxaliplatin 24Radiation 23durvalumab 22Radiotherapy 22Letrozole 22Etoposide 22Nivolumab 21Irinotecan 21Vincristine 20Rituximab 20Capecitabine 20Taxes 19Prednisone 19Lenalidomide 19130-nm albumin-bound paclitaxel 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Crizotinib × 30 days × Clear all
NCT02075840 2026-05-29

ALEX

Hoffmann-La Roche

Phase 3 Completed
303 enrolled 32 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04603807 2026-05-28

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

Hoffmann-La Roche

Phase 3 Active not recruiting
220 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03194893 2026-05-20

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Hoffmann-La Roche

Phase 3 Active not recruiting
200 enrolled
EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Multiple Endocrine Neoplasia Type 2a

Data powered by HemOnc (CC BY 4.0) Colophon âš¡